METIS TECHBIO-P (07666) saw its shares rise more than 11% during the trading session. As of the time of writing, the stock was up 6.96% to HK$17.51, with a turnover of HK$63.37 million. The catalyst for the move was the company's official launch of its AiProtein platform and the antibody design agent AARON. As the fourth core solution driven by METIS TECHBIO-P's AI nano-delivery platform NanoForge, AiProtein, together with AiLNP, AiRNA, and AiTEM, completes the company's end-to-end "Rocket + Satellite" R&D loop encompassing protein design, mRNA sequence design, and LNP design. Notably, on May 18, METIS TECHBIO-P announced a strategic collaboration with GRIT Biotechnology on immunotargeted LNP technology, signing a comprehensive strategic agreement. This partnership is not a simple technology outsourcing arrangement but represents a deep integration between two technology-driven biotech firms in the cutting-edge field of in vivo immunotherapy. METIS TECHBIO-P will leverage its globally first AI nano-delivery platform, NanoForge, to help GRIT Biotechnology overcome delivery bottlenecks for its next-generation cell therapy drugs.